NHS Becomes First Health System Globally to Approve 'Trojan Horse' Cancer Therapy for Multiple Myeloma
Key Insights
The NHS in England has become the first health system worldwide to approve belantamab mafodotin (Blenrep), a novel antibody-drug conjugate therapy for multiple myeloma (search) patients.
Clinical trials demonstrated the treatment delayed disease progression by an average of three years compared to just over one year with standard daratumumab therapy.
Approximately 1,500 patients annually with relapsed or refractory multiple myeloma (search) will be eligible for this targeted therapy through the NHS Cancer Drugs Fund.
The NHS in England has achieved a global healthcare milestone by becoming the first health system worldwide to approve belantamab mafodotin (Blenrep) for multiple myeloma (search) patients, following approval by the National Institute for Health and Care Excellence (NICE) on June 12.
The groundbreaking antibody-drug conjugate therapy, manufactured by GlaxoSmithKline, will be available to approximately 1,500 patients annually with multiple myeloma (search), an incurable bone marrow cancer (search). The treatment targets patients whose cancer has progressed or failed to respond to first-line treatment with lenalidomide.
Revolutionary 'Trojan Horse' Mechanism
Belantamab mafodotin operates through a sophisticated "Trojan horse" mechanism, designed to infiltrate cancer cells (search) before releasing high concentrations of lethal molecules to destroy them from within. This antibody-drug conjugate specifically targets and attaches to cancer cells, representing a significant advancement in precision oncology.
The therapy, which was researched and developed in the UK, will be administered as an infusion every three weeks in combination with bortezomib (injection) and dexamethasone (oral medication).
Clinical Trial Results Demonstrate Superior Efficacy
Clinical trials revealed compelling efficacy data for the combination therapy. In patients with relapsed or refractory multiple myeloma (search), belantamab mafodotin combined with bortezomib and dexamethasone delayed disease progression by an average of three years, compared to just over one year for patients receiving the commonly-used drug daratumumab with the same combination partners.
Professor Peter Johnson, NHS England (search)'s National Clinical Director for Cancer, emphasized the treatment's potential impact: "This new treatment has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family."
Patient Experience Highlights Treatment Promise
Paul Silvester, a 60-year-old patient from Sheffield diagnosed with myeloma in July 2023, experienced remarkable results after receiving belantamab mafodotin through an early access program at Royal Hallamshire Hospital. His initial treatment had failed to halt cancer progression, but within two to three weeks of receiving the first dose of belantamab mafodotin, he achieved remission.
"I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission," Silvester reported. "It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future."
Multiple Myeloma Disease Burden and Treatment Landscape
Multiple myeloma (search) affects more than 6,000 newly diagnosed patients annually in the UK, with an estimated 33,000 people currently living with the disease. The cancer predominantly affects the bone marrow and commonly involves multiple body sites including the spine, skull, pelvis, and ribs.
The disease demonstrates demographic patterns, occurring more frequently in men than women, adults over 60, and individuals with family history. Notably, multiple myeloma (search) is twice as common in Black populations compared to White and Asian populations.
As an incurable condition, multiple myeloma (search) patients typically experience multiple relapses, making treatment focused on halting cancer progression for extended periods while minimizing side effects.
Safety Profile and Monitoring Requirements
The treatment protocol requires comprehensive ophthalmological assessments before initiating therapy and after each of the first three treatments. Documented side effects include ocular toxicity, visual disturbances, blurred vision, dry eyes, and photophobia.
Healthcare System and Industry Impact
NHS England (search) is fast-tracking patient access through immediate funding via the Cancer Drugs Fund. Health Minister Karin Smyth highlighted the broader implications: "This groundbreaking therapy puts the NHS at the forefront of cancer innovation."
Antoine Herbaux, Vice President and Head of Oncology UK at GSK, noted the significance of local innovation: "Belantamab mafodotin was partly discovered in Stevenage, the first patient to receive it in clinical trials was in London, and now the UK is the first country to grant patient access."
Shelagh McKinlay, Director of Research and Advocacy at Myeloma UK (search), emphasized the collaborative effort: "We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma."